Clarity Pharmaceuticals (ASX: $CU6) Equity Raising Announcement

Clarity Pharmaceuticals Limited (ASX: $CU6) has announced a fully underwritten pro rata accelerated non-renounceable entitlement offer to eligible shareholders. The offer aims to raise up to approximately $20 million before costs, with the Retail Entitlement Offer expected to raise up to approximately $11 million before costs. Eligible Retail Shareholders are advised to review the Retail Offer Booklet and accompanying personalised Entitlement and Acceptance Form in full and seek professional advice before making any investment decision.

Executive Commentary on Equity Raising

The company is pleased to announce the equity raising, which is fully underwritten and designed to strengthen our balance sheet. This will enable us to fund our clinical program through to early 2026, allowing us to continue developing our portfolio of radiopharmaceuticals and achieve significant milestones in our therapeutic and diagnostic product pipeline.

Summary of Clarity Pharmaceuticals (ASX: $CU6) Announcement

Clarity Pharmaceuticals (ASX: $CU6) has announced a fully underwritten equity raising of $121 million, comprising a pro rata accelerated non-renounceable entitlement offer and a placement to institutional investors. The offer is expected to strengthen the company's balance sheet and fund its clinical program through to early 2026. The company aims to continue developing its portfolio of radiopharmaceuticals and achieve significant milestones in its therapeutic and diagnostic product pipeline. The offer price per new fully paid ordinary shares in Clarity is $2.55 per share, representing a discount to the last closing price and the 5-day volume weighted average price. The company has also provided details on the choices available to eligible retail shareholders, the application process for new shares under the retail entitlement offer, and the indicative timetable for the offer.